ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.Cancer letters · 2026Trial
- XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.Oncoimmunology · 2025Trial
- Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.Digital discovery · 2026Article
- Combination therapy with HSP90 inhibitors and NanoPulse stimulation synergistically impedes hepatocellular carcinoma and breast cancer growth in mice.Scientific reports · 2026Article
- Review
- CRISPR-StAR enables high-resolution genetic screening in complex in vivo models.Nature biotechnology · 2025Article
- Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review.Medicine · 2025Review
- Article
- Advances in the structures, mechanisms and targeting of molecular chaperones.Signal transduction and targeted therapy · 2025Review
- Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Regulation of RAF family kinases: new insights from recent structural and biochemical studies.Biochemical Society transactions · 2024Review
- Distinct patterns of proteostasis network gene expression are associated with different prognoses in melanoma patients.Scientific reports · 2024Article
- Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal transduction and targeted therapy · 2023Review
- High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.Cell reports. Medicine · 2023Article
- Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.Scientific reports · 2023Article
- Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888.Medical oncology (Northwood, London, England) · 2023Article
- BRAFScience advances · 2023Article
- Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment.International journal of molecular sciences · 2023Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 4 institutions in 1 country.
Zeynep ErogluDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Y Ann ChenDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
Geoffrey T GibneyGeorgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.
Jeffrey S WeberNYU Langone Medical Center, New York, New York.
Ragini R KudchadkarWinship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia.
Nikhil I KhushalaniDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Joseph MarkowitzDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Andrew S BrohlDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Leticia F TettehDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Howida RamadanDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Gina ArnoneDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Jiannong LiDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
Xiuhua ZhaoDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Ritin SharmaDepartment of Tumor Biology, Moffitt Cancer Center, Tampa, Florida.
Lancia N F DarvilleDepartment of Proteomics, Moffitt Cancer Center, Tampa, Florida.
Bin FangDepartment of Proteomics, Moffitt Cancer Center, Tampa, Florida.
Inna SmalleyDepartment of Tumor Biology, Moffitt Cancer Center, Tampa, Florida.
Jane L MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
John M KoomenMolecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Vernon K SondakDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
Keiran S M SmalleyDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida. keiran.smalley@moffitt.org.
Moffitt Cancer Center · USEmory University · USGeorgetown University Medical Center · USNYU Langone Health · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MTissue, Pathology and BioinformaticsP50CA168536 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI MULE, JAMES J. · 2013 to 2017
$8.5MDefining the role of metabolic heterogeneity in melanoma dissemination and therapy escapeK99CA226679 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SMALLEY, INNA · 2018 to 2019
$197kNCI NIH HHS K99 CA226679NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA168536
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdultAgedAmino Acid SubstitutionAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleHSP90 Heat-Shock ProteinsHumansMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoplasm StagingProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF protein, humanHSP90 Heat-Shock ProteinsProtein Kinase InhibitorsProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.